Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 19/20 | 0.59 |
| ▸ | ESR2 | Q92731 | 19/20 | 0.59 |
| ▸ | HSP90AA1 | P07900 | 3/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL745847 | 0.84 | ESR1 (0.62) | ESR1ESR2HSP90AA1 | |
| SCHEMBL5508112 | 0.79 | ESR1 (0.63) | ESR1ESR2HSP90AA1 | |
| SCHEMBL15478599 | 0.79 | CHRNB2 (0.49) | ESR1ESR2HSP90AA1 | |
| SCHEMBL5985206 | 0.79 | MAPT (0.53) | — | |
| SCHEMBL7374829 | 0.76 | GRM4 (0.40) | ESR1ESR2 | |
| SCHEMBL29591513 | 0.76 | BRD4 (0.45) | — | |
| SCHEMBL12646518 | 0.76 | FAAH (0.49) | — | |
| SCHEMBL3524236 | 0.76 | BRD4 (0.45) | — | |
| SCHEMBL12209283 | 0.76 | GRM4 (0.49) | — | |
| SCHEMBL30716972 | 0.76 | GRM4 (0.49) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3704094-B1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2026-03-11 | — | — | EP | disclosed |
| US-20250122188-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2025-04-17 | — | — | US | disclosed |
| US-20240166652-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ABBVIE INC. | 2024-05-23 | — | — | US | disclosed |
| EP-4356971-A2 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | Calico Life Sciences LLC (US) | 2024-04-24 | — | — | EP | disclosed |
| CN-115947681-A | Modulators of integrated stress pathways | 卡里科生命科学有限责任公司 | 2023-04-11 | — | — | CN | disclosed |
| US-20220363678-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2022-11-17 | — | — | US | disclosed |
| CN-109641844-B | Modulators of integrated stress pathways | 卡里科生命科学有限责任公司 | 2022-11-01 | — | — | CN | disclosed |
| CN-109574945-B | Isoxazoline derivatives and their use in agriculture | 东莞市东阳光农药研发有限公司 | 2021-04-20 | — | — | CN | disclosed |
| CN-112189008-A | Modulators of integrated stress pathways | 卡里科生命科学有限责任公司 | 2021-01-05 | — | — | CN | disclosed |
| US-20200361941-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ABBVIE INC. | 2020-11-19 | — | — | US | disclosed |
| US-8263606-B2 | Spiro-oxindole compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2012-09-11 | — | — | US | disclosed |
| EP-2350090-A2 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | Xenon Pharmaceuticals Inc. (CA) | 2011-08-03 | — | — | EP | disclosed |
| US-20110160199-A1 | Aralkyl Substituted Piperidine or Piperazine Derivatives and Their Use for Treating Schizophrenia | JIANGSU GOWORTH INVESTMENT CO. LTD. (CN) | 2011-06-30 | — | — | US | disclosed |
| EP-2322520-A1 | ARALKYL SUBSTITUTED PIPERIDINE OR PIPERAZINE DERIVATIVES AND THEIR USE FOR TREATING SCHIZOPHRENIA | Jiangsu Guohua Investment Co., Ltd (CN) | 2011-05-18 | — | — | EP | disclosed |
| US-20100137299-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2010-06-03 | — | — | US | disclosed |
| WO-2010045251-A2 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS, INC. (CA) | 2010-04-22 | — | — | WO | disclosed |
| US-6380218-B1 | FOR THERAPY OF RESPIRATORY, ALLERGIC, AND INFLAMMATORY DISORDERS COMPRISING ASTHMA, CHRONIC OBSTRUCTIVE PULMONARY DISEASE, ACUTE RESPIRATORY DISEASE SYNDROME, PULMONARY HYPERSENSITIVITY, AND ALLERGIC RHINITIS IN A MAMMAL | PFIZER INC | 2002-04-30 | — | — | US | disclosed |
| EP-0971894-A1 | NICOTINAMIDE DERIVATIVES | Pfizer Products Inc. (US) | 2000-01-19 | — | — | EP | disclosed |
| WO-1998045268-A1 | NICOTINAMIDE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 1998-10-15 | — | — | WO | disclosed |
| US-4888041-A | POST EMERGENCE HERBICIDES | THE DOW CHEMICAL COMPANY (US) | 1989-12-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200361941-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | ESR1 1100/4885ESR2 482/4885HSP90AA1 249/4885 |
| US-20250122188-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | ESR1 1100/4885ESR2 482/4885HSP90AA1 249/4885 |
| US-20110160199-A1 | Aralkyl Substituted Piperidine or Piperazine Derivatives and Their Use for Treating Schizophrenia | REN, GRIK5, CAT | ESR1 4706/4885ESR2 3117/4885HSP90AA1 3562/4885 |
| US-20240166652-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | ESR1 1100/4885ESR2 482/4885HSP90AA1 249/4885 |
| US-20220363678-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | ESR1 1100/4885ESR2 482/4885HSP90AA1 249/4885 |
| US-20100137299-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | TRPV3, TRPV1, TRPC3 | ESR1 1758/4885ESR2 1099/4885HSP90AA1 1122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.